Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Targeting tyrosine kinases in cancer: the second wave.

Baselga J.

Science. 2006 May 26;312(5777):1175-8.

PMID:
16728632
2.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
3.

[Antineoplastic agents targeting tyrosine kinases].

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM.

Tidsskr Nor Laegeforen. 2005 Nov 17;125(22):3115-9. Review. Norwegian.

4.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052
5.

[Tyrosine kinases. New target of anticancer therapy].

Majsterek I, Pytel D, Błasiak J.

Postepy Biochem. 2005;51(3):251-60. Review. Polish.

PMID:
16381169
6.

Inhibiting tyrosine kinases: successes and limitations.

Arteaga CL.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S79-83. Review.

PMID:
14508084
7.
8.

The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.

Eck MJ, Manley PW.

Curr Opin Cell Biol. 2009 Apr;21(2):288-95. doi: 10.1016/j.ceb.2009.01.014. Epub 2009 Feb 11. Review.

PMID:
19217274
9.

Acquired resistance to drugs targeting receptor tyrosine kinases.

Rosenzweig SA.

Biochem Pharmacol. 2012 Apr 15;83(8):1041-8. doi: 10.1016/j.bcp.2011.12.025. Epub 2011 Dec 26. Review.

10.

Commentary: Novel therapies for cancer: why dirty might be better.

Fojo T.

Oncologist. 2008 Mar;13(3):277-83. doi: 10.1634/theoncologist.2007-0090. Review. No abstract available.

11.

Tyrosine kinase inhibitors: a clinical perspective.

Goel S, Mani S, Perez-Soler R.

Curr Oncol Rep. 2002 Jan;4(1):9-19. Review.

PMID:
11734109
12.

[STI571: a summary of targeted therapy].

Czyz M, Jakubowska J.

Postepy Hig Med Dosw (Online). 2006;60:677-96. Review. Polish.

13.

[Kinase inhibitors].

Yamori T, Kong D.

Nihon Rinsho. 2010 Jun;68(6):1059-66. Review. Japanese.

PMID:
20535956
14.

[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].

Grimm CF, Blum HE, Geissler M.

Dtsch Med Wochenschr. 2005 Jun 10;130(23):1438-42. Review. German. No abstract available.

PMID:
15929020
15.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Engelman JA, Settleman J.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5. Review.

PMID:
18325754
16.

Beyond Herceptin and Gleevec.

Fischer OM, Streit S, Hart S, Ullrich A.

Curr Opin Chem Biol. 2003 Aug;7(4):490-5. Review.

PMID:
12941424
17.

[Imatinib and solid tumours].

Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.

Bull Cancer. 2008 Jan;95(1):99-106. doi: 10.1684/bdc.2008.0557. Review. French.

PMID:
18230575
18.

The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.

Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK.

Curr Med Chem. 2007;14(7):735-43. Review.

PMID:
17346159
19.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Deininger MW.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. Epub 2003 Nov 7. Review.

PMID:
14605878
20.

[Molecular therapy of breast carcinoma in the advanced phase].

Foggi P, Amodio A.

Tumori. 2003 Jul-Aug;89(4 Suppl):189-91. Review. Italian.

PMID:
12903589
Items per page

Supplemental Content

Write to the Help Desk